← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Phusis Therapeutics, Inc.
La Jolla, CA
$3,770,399
Total funding
5
Grants
Funding over time
peak $2.1M · FY2013–25$2.5M$1.9M$1.3M$625K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,770,399 · 5
By mechanism
R44$2,085,765 · 1
R01$1,002,731 · 1
R43$512,434 · 2
R21$169,469 · 1
Investigators at Phusis Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Clinical evaluation of a novel AKT/PDK1 inhibitor, PHT-427, for the treatment of multi-field actinitc keratoses$2,085,765
R44 · FY2025 · CA
Inhibiting Multi-Functional ALDOA for Cancer Therapy$504,587
R01 · FY2021 · CA
Inhibiting Multi-Functional ALDOA for Cancer Therapy$498,144
R01 · FY2022 · CA
Targeting mutant KRAS for cancer therapy$287,434
R43 · FY2013 · CA
Inhibiting PLEKHA7 for mutant KRAS therapy$225,000
R43 · FY2014 · CA
Targeting ERK5 for Colorectal Cancer Therapy$169,469
R21 · FY2021 · CA